Sutro Biopharma (STRO) Q1 2024 Earnings
STRO·Reported May 13, 2024·Before market open
Sutro Biopharma reported Q1 2024 revenue of $13.0M, beat analyst consensus of $11.9M by $1.1M. Diluted EPS came in at $-0.95, missed the $-0.92 consensus by $0.03.
Revenue
$13.0Mbeat by $1.1M
Consensus: $11.9MDiluted EPS
$-0.95missed by $0.03
Consensus: $-0.92
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Sutro Biopharma's Q1 2024 earnings report.
Sutro Biopharma (STRO) reported Q1 2024 earnings on May 13, 2024 before market open.
Sutro Biopharma reported revenue of $13.0M and diluted EPS of $-0.95 for Q1 2024.
Revenue beat the consensus estimate of $11.9M by $1.1M. EPS missed the consensus estimate of $-0.92 by $0.03.
You can read the 10-Q periodic report (0000950170-24-058718) directly on SEC EDGAR. The filing index links above go to sec.gov.